Korean wearable robot maker Angel Robotics announced on October 29, 2026 that its Angel Suit H10 walking-assistance exoskeleton completed medical-device registration with Thailand's Food and Drug Administration, according to Korea Biomedical Review. Thailand is the H10's third overseas registration in under a year, following approvals in Malaysia and Vietnam. With this clearance, both the H10 and the company's older Angel Legs M20 gait-rehabilitation robot are now registered in all three markets.
What does the Angel Suit H10 actually do?
The H10 is a wearable robotic brace, an exoskeleton, that straps onto a person's legs and hips to help them walk, sit and stand. It uses seven high-precision sensors paired with real-time body modeling to read what a wearer is trying to do, like shifting weight to take a step, and then adds mechanical assistance at the hip and knee joints to help complete that movement. A built-in resistance mode can simulate the feel of moving through water, used for strength training rather than pure assistance. Users can tune and save a different assistance level for each leg independently, which matters for stroke or injury patients whose two sides often need different support.
The H10 launched in Korea in June 2025 and is pitched as a step below the company's Angel Legs M20, a more intensive gait-rehabilitation robot aimed at patients earlier in recovery. Running both products side by side lets Angel Robotics cover a wider span of a patient's recovery, from early rehabilitation on the M20 to longer-term walking assistance on the lighter H10.
Why does a regulatory filing in Thailand matter?
Medical device registrations are slow and market-specific by design. Each country's health authority independently reviews safety and clinical data before a device can legally be sold or used in hospitals and clinics there, so a Korean approval doesn't automatically carry over to Thailand, Malaysia or Vietnam. Angel Robotics has now cleared all three of the biggest adjacent Southeast Asian markets within about a year, which is fast for a medical device company and signals the company has built a repeatable regulatory playbook rather than treating each filing as a one-off.
That playbook matters more than any single market. Angel Robotics CEO Kong Kyoung-chul, a KAIST mechanical engineering professor who recently returned to lead the company, said the Thailand registration "provides a foundation for expanding the Angel Suit H10's presence" across major Southeast Asian markets. Thailand's own medical device market was valued at $2.29 billion in 2025 and is projected to grow at a 6.22% annual rate through 2029, giving Angel Robotics a reasonably sized market to enter even before it reaches larger targets.
What's next for exoskeleton makers in the region?
Southeast Asia is aging fast, and most of its health systems have far fewer physical therapists per patient than Korea, Japan or the U.S. A wearable robot that lets one therapist supervise assisted walking for a patient, rather than physically supporting them, stretches scarce rehabilitation staff further. That's the opportunity Angel Robotics is chasing, and Kong has said the company's next targets are the U.S. and European markets, where regulatory bars are higher but reimbursement, insurance coverage for medical costs, is more established and could make exoskeletons commercially viable at scale rather than a research curiosity.